Nimbex (Cisatracurium Besilate)

Cisatracurium acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor end‑plate. By blocking acetylcholine binding, it prevents depolarization of skeletal muscle fibers, producing a dose‑dependent, reversible muscle relaxation without initiating a depolarizing phase.

The dose of Nimbex is individualized by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and the specific clinical situation such as intubation or maintenance of paralysis during surgery.

The safety of cisatracurium besilate in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians should weigh potential benefits against possible risks before use in pregnant or nursing patients.

To order Nimbex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The most common alternative to cisatracurium is rocuronium, another non‑depolarizing blocker. Cisatracurium is organ‑independent, undergoing Hofmann elimination, which makes its clearance less affected by renal or hepatic dysfunction compared with rocuronium, which is primarily hepatically cleared.

Nimbex is supplied as an injectable solution that must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken to preserve stability.

Nimbex is administered intravenously, either as a rapid bolus to facilitate intubation or as a continuous infusion to maintain muscle relaxation during surgery. Administration is performed by qualified healthcare professionals in a controlled clinical setting.

The most serious adverse events include anaphylactic reactions, prolonged neuromuscular blockade that may require extended ventilation support, and severe hypotension that can be refractory to standard measures. Prompt recognition and appropriate supportive care are essential.

Nimbex should be avoided in patients with a known hypersensitivity to cisatracurium or any component of the formulation. Caution is also advised in individuals with severe hepatic or renal impairment, and in pregnant or lactating women when the benefit does not clearly outweigh the potential risk.